Advertisement

Clinical use of anti-obsesity agents

Chapter
Part of the Current Status of Modern Therapy book series (CSMT, volume 2)

Abstract

It has been estimated that well over 5 million prescriptions were written for the anti-obesity drugs in 1966 in the United Kingdom. Since then, the number of scripts issued has steadily fallen to ‘only’ slightly more than 3 million prescriptions in 1975. This figure would suggest that either the anti-obesity drugs are effective or that they are being extensively over-prescribed. At present, more than one-third of subjects enrolling in a slimming organization will have previously taken at least one anti-obesity agent, and more than three-quarters of subjects referred by general practitioners to a hospital obesity clinic will have previously received drug therapy. It follows that subjects with a weight problem of sufficient concern to make them seek medical attention may, at present, reasonably expect to be prescribed a weight-reducing drug. Certainly most general practitioners prescribe at least one anti-obesity agent, and the majority of patients say that they find such drugs are helpful. Indeed, in a recent survey undertaken by the Consumers’ Association, appetite-suppressant drugs were rated by women slimmers to be the best method of achieving rapid weight loss. However, only 16% of these women considered that dieting with the aid of appetite-reducing pills was a successful method of producing a long-term weight loss1.

Keywords

Thyroid Hormone Anorexia Nervosa Lactic Acidosis Promote Weight Loss Substantial Weight Loss 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Consumers Association (1978). Which? Way to Slim. (Portsmouth: Eyre and Spottiswoode Ltd.).Google Scholar
  2. 2.
    Cornell, P. H. (1975). In M. N. G. Dukes (ed.). Mylers Side Effects of Drugs, vol. 8, p. 1. (Amsterdam-Oxford: Excerpta Medica).Google Scholar
  3. 3.
    Mackay, R. H. G. (1973). Long-term use of diethylpropion in obesity. Curr. Med. Res. Opinion, 8, 489.CrossRefGoogle Scholar
  4. 4.
    Le Riche, W. H. and Csima, A. (1967). A long acting appetite suppressant drug. Canad. Med. Assoc. J., 97, 1016.Google Scholar
  5. 5.
    Allen, G. S. (1977). A double blind clinical trial of diethylpropion hydrochloride, mazindol and placebo in the treatment of exogenous obesity. Curr. Ther. Res., 22, 678.Google Scholar
  6. 6.
    McQuarrie, H. G. D. (1975). Clinical assessment of the use of an anorectic drug in a total weight reduction programme. Curr. Ther. Res., 17, 437.Google Scholar
  7. 7.
    Bolding, P. T. (1974). Diethylpropion hydrochloride: an effective suppressant. Curr. Ther. Res., 16, 40.Google Scholar
  8. 8.
    Nolan, G. R. (1975). Use of an anorexic drug in a total weight reduction program in prvate practice. Curr. Ther. Res., 18, 332.Google Scholar
  9. 9.
    Stewart, D. A., Bailey, J. D. and Patell, H. (1970). Tenuate dospan as an appetite suppressant in the treatment of obese children. App. Therapeut., 12, 34.Google Scholar
  10. 10.
    Munro, J. F., McCuish, A. C., Wilson, E. M. and Duncan, L. J. P. (1968). Comparison in continuous and intermittent anorectic therapy in obesity. Br. Med. J., 1, 352.CrossRefGoogle Scholar
  11. 11.
    Campbell, C. J., Bhalla, I. P., Steele, H. M. and Duncan, L. J. P. (1977). A controlled trial of phentermine in obese diabetic patients. Practitioner, 218, 851.Google Scholar
  12. 12.
    Langlois, K. J., Forbes, J. A., Bell, C. W. and Grant, G. F. (Jr). (1974). A double blind clinical evaluation of the safety and efficacy of phentermine hydrochloride (fastin) in the treatment of exogenous obesity. Curr. Ther. Res., 16, 289.Google Scholar
  13. 13.
    Truant, A. P., Lawrence, P. A. and Cobb, S. (1972). Phentermine resin as an adjunct in medical weight reduction: a controlled randomised double blind prospective study. Curr. Ther. Res., 14, 726.Google Scholar
  14. 14.
    Moe, J. F. (1977). Phentermine hydrochloride therapy for exogenous obesity: an evaluation of interrupted therapy. Curr. Ther. Res., 22, 666.Google Scholar
  15. 15.
    Harrison, L. C., King-Roach, A. P. and Sandy, K. C. (1975). Effects of mazindol on carbohydrate and insulin metabolism in obesity. Metabolism, 24(12), 1353.CrossRefGoogle Scholar
  16. 16.
    Wallace, A. G. (1976). An 448 sandoz (mazindol) in the treatment of obesity. Med. J. Aust., 1, 343.Google Scholar
  17. 17.
    Maclay, W. P. and Wallace, M. G. (1977). A multicentre general practice trial of mazindol in the treatment of obesity. Practitioner, 218.Google Scholar
  18. 18.
    Clinical trials: comparative merits of two weight reducing drugs (1978). (A report from the General Practice Research Group). J. Pharmacotherapy, 1, 35.Google Scholar
  19. 19.
    Bradley, M. J., Blum, N. J. and Scheib, R. K. (1974). Mazindol in obesity with known cardiac disease. J. Int. Med. Res., 2, 347.Google Scholar
  20. 20.
    Bandisode, M. S. and Boshell, B. R. (1975). Double blind clinical evaluation of mazindol (42–558) in obese diabetics. Curr. Ther. Res., 18(6), 816.Google Scholar
  21. 21.
    Schwartz, L. N. (1975). A non-amphetamine anorectic agent: preclinical background and a double blind clinical trial. J. Int. Med. Res., 3, 328.Google Scholar
  22. 22.
    Heber, K. R. (1975). Double blind trial of mazindol in overweight patients. Med. J. Aust., 2, 566.Google Scholar
  23. 23.
    Gomez, G. (1975). Obese patients in general practice: a comparison of the anorectic effects of mazindol, fenfluramine and placebo. Clin. Trials J., 12, 38.Google Scholar
  24. 24.
    Smith, R. G., Innes, J. A. and Munro, J. F. (1975). Double blind evaluation of mazindol in refractory obesity. Br. Med. J., 3, 284.CrossRefGoogle Scholar
  25. 25.
    Sharma, R. K., Collipp, P. J., Rezvani, I., Strimas, J., Maddaiah, V. T. and Rezvani, E. (1973). Clinical evaluation of the anorexic activity and safety of 42–558 in children. Clin. Pediat., 12, 145.CrossRefGoogle Scholar
  26. 26.
    Allen G. S. (1977). A double blind clinical trial of diethylpropion hydrochloride, mazindol and placebo in the treatment of exogenous obesity. Curr. Ther. Res., 22, 678.Google Scholar
  27. 27.
    Smith, D. E. (1974). A new anorexiant. Rocky Mountain Med. J., 71(1), 41.Google Scholar
  28. 28.
    Sedgwick, J. P. (1975). Mazindol in the treatment of obesity. Practitioner, 214, 418.Google Scholar
  29. 29.
    Conte, A. (1973). Evaluation of sanorex — a new appetite suppressant. Obesity/ Bariatric Med., 2, 104.Google Scholar
  30. 30.
    Pinder, R. M., Brogden, R. N., Sawyer, P. R., Spreight, P. M. and Avery, G. S. (1975). Fenfluramine: A review of its pharmacological properties and therapeutic efficacy in obesity. Drugs, 10(4), 241.CrossRefGoogle Scholar
  31. 31.
    Innes, J. A., Watson, M. L., Ford, M. J., Munro, J. F., Stoddart, M. E. and Campbell, D. B. (1977). Plasma fenfluramine levels, weight loss and side effects. Br. Med. J., 2, 1322.CrossRefGoogle Scholar
  32. 32.
    Doar, J. W. H., and Thomson, M. E. (1978). The influence of diet and fenfluramine on plasma sugar and insulin levels in patients with newly diagnosed maturity onset diabetes mellitus. Gurr. Med. Res. Opin., (in press).Google Scholar
  33. 33.
    Stowers, J. M. and Bewsher, P. D. (1969). Studies on the mechanism of weight reduction by phenformin. Postgrad. Med. J. 2, 104.Google Scholar
  34. 34.
    Cairns, A., Shalet, S., Marshall, A. J. and Hartog, M. (1977). A comparison of phenformin and metformin in the treatment of maturity onset obese diabetes. Diabete et Metabolisme, 3, 183.Google Scholar
  35. 35.
    Patel, D. P. and Stowers, J. M. (1964). Phenformin in weight reduction of obese diabetics. Lancet, 2, 282.CrossRefGoogle Scholar
  36. 36.
    Clarke, B. F. and Duncan, L. J. P. (1968). Comparison of chlorpropamide and metformin treatment on weight and blood glucose response of uncontrolled obese diabetics. Lancet 1, 123.CrossRefGoogle Scholar
  37. 37.
    Faludi, G., Chayes, Z. and Gerber, P. (1968). Rational treatment of the obese diabetic. Postgrad. Med. J., 43(21), 92.Google Scholar
  38. 38.
    Lavieuville, M. and Isnard, F. (1975). Retrospective study of the cardiovascular fate of 190 diabetics treated for 5 years or more with biguanides alone. Journees de Diabetologie Hotel-Dieu, p.341.Google Scholar
  39. 39.
    Mursky, S. and Schwartz, M. (1966). Phenformin diabetic control and body weight. J. Mount Sinai Hosp., 33(2), 180.Google Scholar
  40. 40.
    Clarke, B. F. and Campbell, I. W. (1977). Comparison of metformin and chlorpropamide in non obese, maturity onset diabetics uncontrolled by diet. Br. Med. J., 2, 1576.CrossRefGoogle Scholar
  41. 41.
    Roginsky, M. S. and Barnett, J. (1966). Double blind study of phenethyl diguanide in weight control of obese nondiabetic subjects. Am. J. Clin. Med., 19(4), 223.Google Scholar
  42. 42.
    Munro, J. F., MacCuish, A. C., Marshall, A., Wilson, E. M. and Duncan, L. J. P. (1969). Weight reducing effect of biguanides on obese non-diabetic women. Br. Med. J., 2, 13.CrossRefGoogle Scholar
  43. 43.
    Lawson, A. A. H., Strong, J. A., Roscoe, P. and Gibson, A. (1970). Comparisons of fenfluramine and metformin in treatment of obesity. Lancet, 1, 437.CrossRefGoogle Scholar
  44. 44.
    Lutjens, A. and Smit, J. L. J. (1976). Effect of biguanide treatment in obese children. Helv. Paediat. Acta, 31, 473.Google Scholar
  45. 45.
    Miller, D. S. and Parsonage, S. (1975). Resistance to slimming; adaptation or illusion. Lancet, 1, 773.CrossRefGoogle Scholar
  46. 46.
    Gwinup, G. and Poucher, R. (1967). A controlled study of thyroid analogs in the therapy of obesity. Am. J. Med. Sci., 254, 416.CrossRefGoogle Scholar
  47. 47.
    Bray, G. A. and Greenway, F. L. (1976). Pharmacological approaches to treating the obese patients. In M. J. Albrink (ed.), Clinics in Endocrinology and Metabolism, vol. 54, p.455. (London, Philadephia and Toronto: J. B. Saunders & Co. Ltd).Google Scholar
  48. 48.
    Kaplan, N. M. and Jose, A. (1970). A controlled study of thyroid analogs in the therapy of obesity. Am. J. Med. Sci., 260, 416.Google Scholar
  49. 49.
    Hollingsworth, D. R., Amatruda, T. T. (Jr) and Scheig, R. (1970). Quantitative and qualitative effects of L-triiodithyrionine in massive obesity. Metabolism, 19, 934.CrossRefGoogle Scholar
  50. 50.
    Asher, W. L. and Harper, M. W. (1973). Effect of human chorionic gonado-trophin on weight loss, hunger and feeling of well being. Am. J. Clin. Nutr., 26, 211.Google Scholar
  51. 51.
    Hirsch, J. and Von Itallie, T. B. (1973). The treatment of obesity. Am. J. Clin. Nutr., 26, 1039.Google Scholar
  52. 52.
    Quaade, F. (1974). Untraditional treatment of obesity. In W. L. Burland, P. A. Samuel and J. Yudkin (eds). Obesity. (Edinburgh, London and New York: Churchill Livingstone).Google Scholar
  53. 53.
    Thorner, M. O., McNeilly, A. S., Hagan, C. and Besser, G. M. (1974). Long term treatment of galactorrhoea and hypogonadism with bronocriptine. Br. Med. J., 2, 419.CrossRefGoogle Scholar
  54. 54.
    Harrower, A. D. B., Yap, P. L., Nairn, I. M., Walton, H. J., Strong, J. A. and Craig, A. (1977). Growth hormone, insulin and prolactin secretion in anorexia nervosa and obesity during bromocriptine treatment. Br. Med. J., 2, 156.CrossRefGoogle Scholar
  55. 55.
    Quaade, F., Pakkenberg, H. and Juhl, E. (1974). Levo dopa as a treatment of obesity. Acta Med. Scand., 195, 129.CrossRefGoogle Scholar
  56. 56.
    Johanson, A. J. and Knorr, N. J. (1974). Treatment of anorexia nervosa by levo dopa. Lancet, 2, 591.CrossRefGoogle Scholar
  57. 57.
    Scoville, B. A. (1973). Review of amphetamine-like drugs by the Food and Drug Administration. In G. A. Bray (ed.) Obesity in Perspective, p.441. (DHEW Publication No. (NIH) 75-707).Google Scholar
  58. 58.
    Seaton, D. A., Duncan, L. J. P. and Rose, K. (1961). Diethylproprion in the treatment of ‘refractory’ obesity. Br. Med. J., 1, 1009.CrossRefGoogle Scholar
  59. 59.
    Seaton, D. A., Rose, K. and Duncan, L. J. P. (1964a). A comparison of the appetitite suppressing properties of dexamphetamine and phentermine. Scot. Med. J., 9, 482.Google Scholar
  60. 60.
    Seaton, D. A., Rose, K. and Duncan, L. J. P. (1964b). Sustained action chlorphentermine in the correction of refractory obesity. Practitioner, 193, 698.Google Scholar
  61. 61.
    Munro, J. F., Seaton, D. A. and Duncan, L. J. P. (1966). Treatment of refractory obesity with fenfluramine. Br. Med. J., 2, 624.CrossRefGoogle Scholar
  62. 62.
    Silverstone, J. R., Cooper, R. M. and Begg, R. R. (1970). A comparative trial of fenfluramine and diethylpropion in obesity. Br. J. Clin. Pract., 24(10) 624.Google Scholar
  63. 63.
    Philips, B. L. D. (1977). Treatment of obesity: comparison of diethylpropion and fenfluramine. Clin. Trials. J., 14(2) 1.Google Scholar
  64. 64.
    Follows, O. J. (1971). A comparative trial of fenfluramine and diethylpropion in obese, hypertensive patients. Br. J. Clin. Pract., 25, 5.Google Scholar
  65. 65.
    Steel, J. M., Munro, J. F. and Duncan, L. J. P. (1973). A comparative trial of different regimes of fenfluramine and phentermine in obesity. Practitioner, 211, 232.Google Scholar
  66. 66.
    Stunkard, A., Rickeis, K. and Hesbacher, P. (1973). Fenfluramine in the treatment of obesity. Lancet, 1, 503.CrossRefGoogle Scholar
  67. 67.
    Vernace, B. J. (1974). Controlled comparative investigations of mazindol, D-amphetamine and placebo. Obesity and Bariatric Med., 3, 124.Google Scholar
  68. 68.
    Kornhaber, A. (1973). Obesity-depression: clinical evaluation with a new anorexigenic agent. Psychosomatics, 14, 162.Google Scholar
  69. 69.
    Silverstone, T. (1974), Intermittent treatment with anorectic drugs. Practitioner, 212, 245.Google Scholar
  70. 70.
    Asher, W. L. (1978). Personal communication.Google Scholar
  71. 71.
    Enzi, G., Baritussio, A., Machiori, E. and Crepaldi, G. (1976). Short term and long term clinical evaluation of non-amphetamine anorexiant (mazindol) in the treatment of obesity. J. Int. Med. Res., 4, 305.Google Scholar
  72. 72.
    Hudson, K. D. (1977). The anorectic and hypotensive effect of fenfluramine in obesity. J. Roy. Coll. of Gen. Pract., 27, 497.Google Scholar
  73. 73.
    Haugen, H. N. (1975). Double blind cross-over study of a new appetite suppressant. Eur. J. Clin. Pharmacol. 8, 71.CrossRefGoogle Scholar
  74. 74.
    Carney, D. E. and Tweddell, E. D. (1975). Double blind evaluation of long acting diethylproprion hydrochloride in obese patients from a general practice. Med. J. Amt., 1, 13.Google Scholar
  75. 75.
    Miach, P. J., Thomson, W., Doyle, A. E. and Louis, W. J. (1976). Double blind cross-over evaluation of mazindol in the treatment of obese hypertensive patients. Med. J. Aust., 2, 378.Google Scholar
  76. 76.
    British National Formulary (1976–78) (England: Hazell Watson & Viney Ltd, Aylesbury, Bucks).Google Scholar
  77. 77.
    Lasagna, L. (1973). Attitudes towards appetite suppressants. J. Am. Med. Assoc, 225, 44.CrossRefGoogle Scholar
  78. 78.
    Smith, R. C. F. (1962). The long term control of obesity using sustained release appetite suppressants. Br. J. Clin. Pract., 16, 6.Google Scholar
  79. 79.
    Craddock, D. (1973). Obesity and its Management (2nd edn). (London and New York: Churchill Livingstone).Google Scholar
  80. 80.
    Matthews, P. A. (1975). Diethylpropion in the treatment of obese patients seen in general practice. Curr. Ther. Res., 17, 340.Google Scholar

Copyright information

© MTP Press Limited 1979

Authors and Affiliations

There are no affiliations available

Personalised recommendations